10/27/2022

Bioventure invests as lead investor in PROVIREX Genome Editing Therapies GmbH, a Hamburg-based biotech company focusing on infectious diseases, primarily using a genome editing technology newly developed by its founders. PROVIREX relies on highly specific designer recombinases that enable absolutely precise editing of the human genome. This technology can be used, for example, to reverse infections with HIV, the virus that causes AIDS.

PROVIREX has now succeeded in winning Bioventure, a well-known and successful life science investor, which will finance the company for the next four years together with IFB Innovationsstarter GmbH in order to further advance the development of the innovative technology. On Thursday, October 27, 2022, the official go-ahead for the development of a therapy hub for curing HIV was given at an exclusive press event in Hamburg at Factory Hammerbrooklyn.

Founded in 2001, Bioventure is a successful boutique investment firm based in Göttingen, Germany, with a focus on life sciences and biotechnology. Bioventure founds and manages financing companies, giving (semi-) professional investors access to carefully selected and exclusive investment opportunities and companies such as PROVIREX. In doing so, the companies are financed through to at least one significant value inflection point.

Your Bioventure contact persons are:

Dr. Erik Hoppe

Nico Straub